Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Net Cash Flow (2019 - 2025)

Biodesix's Net Cash Flow history spans 7 years, with the latest figure at $2.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 146.17% year-over-year to $2.4 million; the TTM value through Dec 2025 reached -$7.3 million, down 18507.69%, while the annual FY2025 figure was -$7.3 million, 18507.69% down from the prior year.
  • Net Cash Flow reached $2.4 million in Q4 2025 per BDSX's latest filing, up from -$4.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $30.7 million in Q2 2024 to a low of -$17.8 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$2.2 million, with a median of -$6.0 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: crashed 562.17% in 2021, then surged 1092.06% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$15.2 million in 2021, then surged by 283.63% to $27.9 million in 2022, then tumbled by 76.91% to $6.4 million in 2023, then crashed by 180.09% to -$5.2 million in 2024, then skyrocketed by 146.17% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's Net Cash Flow are $2.4 million (Q4 2025), -$4.1 million (Q3 2025), and $3.1 million (Q2 2025).